knowledge -WSS

knowledge

author：knowledge 2025-10-01 22:48:33 - browse：977

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Lab trade group sues FDA to halt regulation of lab

Wikipedia

hotspot

WSS

iTeos Therapeutics debuts first data on TIGIT

Heat waves linked to early deliveries, preterm births in new study

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

For longer

Biohaven protein

Adam's Biotech Scorecard: Do Sarepta's exon

knowledge

knowledge

explore

How to save PrEP access — and even expand it

Scientists successfully use ultrasound imaging to map brain activity

Anesthesiologist group: stop taking Ozempic before surgery

Childbirth

Novavax promises a turnaround & Lilly roils the obesity market

At flashy new research hub, AstraZeneca lays out ambitious growth goals

United colonoscopy coverage change 'may cost lives,' doctors say

Liver decline slowed by off

ChatGPT in medicine: STAT answers readers' burning questions

Biogen joins immunology wave with $1.15 billion acquisition of HI

hotspot

Heat waves linked to early deliveries, preterm births in new study

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Focused ultrasound for uterine fibroids: an uphill battle

Focused ultrasound for uterine fibroids: an uphill battle

Report: NIH

Wikipedia

hotspot

hotspot

entertainment